Cargando…
Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico
Background: The aim of this analysis was to characterize the pharmacokinetics (PK) of sublingual buprenorphine (BUP) and its metabolites (buprenorphine glucuronide; BUP-g, norbuprenorphine; Nor-BUP, and norbuprenorphine glucuronide; Nor-BUP-g) in opioid use disorder (OUD) patients in Puerto Rico (PR...
Autores principales: | Santiago, Darlene, Mangas-Sanjuan, Victor, Melin, Kyle, Duconge, Jorge, Zhao, Wenchen, Venkataramanan, Raman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766849/ https://www.ncbi.nlm.nih.gov/pubmed/33352843 http://dx.doi.org/10.3390/pharmaceutics12121226 |
Ejemplares similares
-
348 Translating a precision dosing approach for opioid use disorder in Puerto Rico: Pilot testing of the clinical utility and patient/provider acceptability
por: Santiago, Darlene, et al.
Publicado: (2023) -
A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder
por: Seguí, Hemanuel Arroyo, et al.
Publicado: (2020) -
2198: Gender differences in the pharmacology of buprenorphine sublingual tablets in Hispanics/Latinos: An underrepresented population
por: Ivelisse Santiago, Darlene, et al.
Publicado: (2018) -
Treating Opioid Use Disorder in Puerto Rico During the COVID-19 Pandemic: Providers’ Leadership Efforts in Unprecedented Times
por: Quiñones, Darlene Santiago, et al.
Publicado: (2021) -
Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine/Naloxone Films: A Case Series
por: Cedeño, Erica, et al.
Publicado: (2022)